Indian stocks: Visit www.stage2stocks.com →

Celularity Inc. Class A

Stage 2 · Advancing · week 4

As of Oct 22, 2026, Celularity is in Stage 2, the uptrend phase, now in week 4 (since Oct 1, 2026). It closed at $1.05, 50.0% below its 52-week high and below its 200-day average, which is falling.

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. More about the company

$1.05
-0.94% today
$34.1M · Micro cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is CELU early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 23w
S4 29w
S4 15w
S4 22w
S4 17w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 23w → S1 6w → S2 7w → S3 8w → S4 29w → S1 2w → S4 15w → S1 9w → S2 10w → S3 5w → S4 22w → S1 3w → S4 17w → S1 4w → S2 3w current
Total tracked: 165 weeks across 15 stage runs.

CELU among Biotechnology348th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…348CELUStage 2 · wk 424−8.7%
vs 52W High
-50.0%
$0.60 lo$2.10 hi
50.0% below 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 4
1w13w26w
Week 4, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
-4.5%
200 DMA: $1.10 · sloping down
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.03x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
→
Short-term trend flat
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
-8.7%
3M
+40.0%
6M
-6.3%
YTD
-13.2%
1Y
-48.0%
Scan Membership
Breakout Watch
Latest: 2024-03-11
4 appearances in last 60 days. First seen: 2020-06-19.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 4 · Vol 0.03x
2026-10-21S2
Wk 3 · Vol 0.04x
2026-10-20S2
Wk 3 · Vol 0.01x
2026-10-19S2
Wk 3 · Vol 0.02x
2026-10-16S2
Wk 3 · Vol 0.01x
2026-10-15S2
Wk 3 · Vol 0.01x
2026-10-14S2
Wk 2 · Vol 0.02x
2026-10-13S2
Wk 2 · Vol 0.01x
2026-10-12S2
Wk 2 · Vol 0.01x
2026-10-09S2
Wk 2 · Vol 0.01x
2026-10-08S2
Wk 2 · Vol 0.02x
2026-10-07S2
Wk 1 · Vol 0.01x
Moving averages & range
50 DMA
$1.30
200 DMA
$1.10
52W High
$2.10
52W Low
$0.60
5D Low
$1.05
Resistance levels (recent highs)
20d High
$1.71
60d High
$2.10
120d High
$2.10
250d High
$2.10
Next resistance
+62.9%
to 20d High
Dividend Yield
0.00%
P/B -0.9

Celularity: quick answers

What stage is Celularity in?

As of Oct 22, 2026, Celularity (CELU) is in Stage 2, the uptrend phase. It entered Stage 2 on Oct 1, 2026 and is in week 4. What the four stages mean

Is Celularity in an uptrend?

Yes. Celularity is in a Stage 2 uptrend. It trades 4.5% below its 200-day average, which is falling.

How far is Celularity from its 52-week high?

Celularity closed at $1.05 on Oct 22, 2026, 50.0% below its 52-week high of $2.10. Its 52-week low is $0.60.

How has Celularity performed over the past year?

As of Oct 22, 2026, Celularity is down 48.0% over the past year and down 13.2% so far in 2026.

Which sector and industry is Celularity in?

Celularity is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.